Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. 2004

Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
Preventive Medical Center, Tohoku Rosai Hospital, Sendai, Japan. munakata.@tohokuh.rofuku.go.jp

BACKGROUND The aim of this study was to compare the effects of long-term antihypertensive treatment on brachial-ankle pulse wave velocity (PWV), a marker of systemic arterial stiffness, between angiotensin II receptor blocker valsartan and long-acting calcium channel blocker nifedipine coat-core. METHODS Forty-one patients (54 +/- 3 years of age, 20 men and 21 women) with essential hypertension (155 +/- 3/95 +/- 3 mm Hg) were randomly allocated to the treatment with valsartan (80 mg once daily) or nifedipine coat-core (20 mg once daily). Brachial-ankle PWV and 24-h ambulatory blood pressures (BP) were measured before and 3 months after treatment. RESULTS Baseline data did not differ between the valsartan and nifedipine groups. The PWV also was similar between the groups (1669 +/- 65 v 1622 +/- 64 cm/sec). Three months of treatment similarly reduced resting systolic and diastolic BP (nifedipine, -18.4 +/- 4.2/-11.9 +/- 2.7 mm Hg; valsartan, - 17.4 +/- 3.3/-9.8 +/- 2.1 mm Hg, all P < .001). The PWV was significantly reduced compared with baseline values in the valsartan group (-195 +/- 42 cm/sec, P < 0.001) but not in the nifedipine group (-69 +/- 40 cm/sec, NS). The 24-h mean heart rate increased in the nifedipine group but remained unchanged in the valsartan group, although BP were similarly lowered for 24 h. A tachycardic response was associated with an increase or lesser reduction in PWV in a group treated with nifedipine (r = 0.584, P < .01). CONCLUSIONS These data suggest that long-term treatment with valsartan could reduce arterial stiffness better than nifedipine-coat core. The favorable vascular effect of valsartan was due in part to its nonhypotensive effect. The expected decrease in arterial stiffness may be offset by reflex sympathetic activation in some patients treated with nifedipine.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068756 Valsartan A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. CGP 48933,Diovan,Kalpress,Miten,N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine,Nisis,Provas,Tareg,Vals,48933, CGP
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
May 2009, Hypertension research : official journal of the Japanese Society of Hypertension,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
January 2017, Journal of clinical hypertension (Greenwich, Conn.),
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
February 2019, Journal of clinical hypertension (Greenwich, Conn.),
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
June 2012, International journal of cardiology,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
January 2003, Drugs,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
May 2003, Blood pressure. Supplement,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
December 1988, Journal of hypertension,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
December 2005, Hypertension research : official journal of the Japanese Society of Hypertension,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
January 2008, Journal of glaucoma,
Masanori Munakata, and Akio Nagasaki, and Tohru Nunokawa, and Toshiaki Sakuma, and Hiroshi Kato, and Kaoru Yoshinaga, and Takayoshi Toyota
December 2018, International journal of cardiology,
Copied contents to your clipboard!